SCHEMBL10242936

SCHEMBL10242936

CCCNC(=O)Cc1cccc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.62
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA3 P07451 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA5A P35218 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
CA5B Q9Y2D0 1/20 0.61
KMT2A Q03164 4/20 0.60
KDM4E B2RXH2 2/20 0.60
ALDH1A1 P00352 2/20 0.60
MEN1 O00255 2/20 0.60
MAPT P10636 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
ATM Q13315 1/20 0.58
HPGD P15428 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31047581 0.88 CA12 (0.67) PTPN1CA12CA1CA2CA3
SCHEMBL31047588 0.88 CA12 (0.67) PTPN1CA12CA1CA2CA3
SCHEMBL10717943 0.88 CA12 (0.67) PTPN1CA12CA1CA2CA3
SCHEMBL9059823 0.88 CA12 (0.67) PTPN1CA12CA1CA2CA3
SCHEMBL6890681 0.86 CA12 (0.63) PTPN1CA12CA1CA2CA3
SCHEMBL28316286 0.84 CA12 (0.73) PTPN1CA12CA1CA2CA3
SCHEMBL7354821 0.82 CA12 (0.66) PTPN1CA12CA1CA2CA3
SCHEMBL28570819 0.82 PTPN1 (0.74) PTPN1CA12CA1CA2CA3
SCHEMBL7750217 0.81 ATM (0.58) PTPN1CA12CA1CA2CA3
SCHEMBL8691063 0.81 MTNR1A (0.72) PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PTPN1 560/4885CA12 2721/4885CA1 3677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.